Thus, our findings align with existing literature on the pro-immunogenic role of cGAS/STING–IFN signaling and provide mechanistic insight into how PRMT1 loss may enhance anti-tumor immunity without contradicting the broader understanding of inflammation’s dual roles in cancer. The gene discussed is STING1; the disease is neoplasm.